Project Details
Description
Engineering iPSC-derived lymphocytes with recombinant Fc?? receptors for enhanced tumor cell targeting by therapeutic antibodies
| Status | Active |
|---|---|
| Effective start/end date | 10/15/19 → 10/15/24 |
Funding
- FATE THERAPEUTICS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.